IPP and neoplasm: IPP is produced as an intermediate of the mevalonate pathway, and the dysregulation of this pathway in transformed cells or the pharmacological inhibition by aminobisphosphonate causes an accumulation of IPP in tumor cells, which leads to their killing by activated Vγ9Vδ2 T cells [6].